Skip to main content

ADVERTISEMENT

Andrew Cournoyer, RPh, MBA

Journeying Through the Past, Present, and Future of Medicare Part D
Pharma Insights
06/17/2020
This article explores the beginnings of Medicare Part D and the different dynamics driving current and future change for various stakeholders including the Centers for Medicare & Medicaid Services, plan sponsors,...
This article explores the beginnings of Medicare Part D and the different dynamics driving current and future change for various stakeholders including the Centers for Medicare & Medicaid Services, plan sponsors,...
This...
06/17/2020
Journal of Clinical Pathways
Pharma Insights
10/12/2016
The use of formulary exclusion lists is expanding—and such lists are beginning to shape the market by further limiting available drugs for narrow therapeutic areas while reducing redundancy of options in broader...
The use of formulary exclusion lists is expanding—and such lists are beginning to shape the market by further limiting available drugs for narrow therapeutic areas while reducing redundancy of options in broader...
The...
10/12/2016
Journal of Clinical Pathways
Pharma Insights
09/19/2017
The use of formulary exclusion lists continues to expand, with clear impacts to the perception and use of all related medications. Annual updates to these lists suggest a need for careful evaluation by benefit...
The use of formulary exclusion lists continues to expand, with clear impacts to the perception and use of all related medications. Annual updates to these lists suggest a need for careful evaluation by benefit...
The...
09/19/2017
Journal of Clinical Pathways
Pharma Insights
04/22/2021
The continued rise in health care spending continues to have a profound effect on the US economy and health care payers. The three complex drivers contributing to these increases include hospital, outpatient, and...
The continued rise in health care spending continues to have a profound effect on the US economy and health care payers. The three complex drivers contributing to these increases include hospital, outpatient, and...
The...
04/22/2021
Journal of Clinical Pathways
Pharma Insights
12/05/2022
The authors discuss how a strategic HEOR evidence-generation plan that comprehensively communicates the value of a new drug helps to ensure that patients have access to innovative drugs and health care stakeholders have access to data to...
The authors discuss how a strategic HEOR evidence-generation plan that comprehensively communicates the value of a new drug helps to ensure that patients have access to innovative drugs and health care stakeholders have access to data to...
The authors discuss how a...
12/05/2022
Journal of Clinical Pathways